Prabhat Singh

CEO & Managing Director

In the context of the dynamic environment across pharmaceutical, bio-technology and nutraceuticals, Contract Research Organizations (CROs) have emerged as important players in facilitating companies to introduce innovation-driven products more accurately and efficiently.

Given the shortened life cycles of products and the increasing regulatory burden, it is placing immense pressure on companies to take on the assistance of CROs with research expertise and willingness to be flexible. With the development of biologically active ingredient products such as enzymes, probiotics, and nutraceuticals, this pressure has increased even further.

Given this highly competitive market which demands specialized knowledge and end-to-end integration, Fido Pharma has been successfully hand-holding its clients at every step, leading to their clinical success and delivering to their clients.

Carving a Niche

Fido Pharma offers a unique CRO model to the extent of merging deep scientific capability with a high-profile client-focused approach. It has been meticulously developed to focus its services around enzymes (Serratiopeptidase, Trypsin, Trypsin-Chymotrypsin, Papain, Bromelain, Pancreatin), probiotics (Lactobacillus sp, Bifidobacterium sp, Bacillus sp, Saccharomyces sp, Streptococcus sp, Aspergillus sp), nutraceuticals (Myo-Inositol, D-Chiro Inositol, Hyaluronic Acid, Sodium Hyaluronate, L-Glutathione Reduced, Chondroitin Sulfate, N-Acetyl L-Cysteine, S-Adenosyl L-Methionine) in its manufacturing unit 1, and their complicated formulations in manufacturing unit 2.

The firm has always refrained from working like traditional CROs who provide generalized services across a wide array of therapeutic areas. This level of detailing enables it to offer its customer bespoke solutions, to specifically mitigate the technical, regulatory, and logistical complications which are unique to every product portfolio. Customers who have used enzyme or probiotic-based therapy solutions encountered many pitfalls pertaining to formulation stability, regulatory definition, and strain viability.

Understanding this, Fido Pharma believes in offering practical, science evidence-based solutions that offer simplicity to the developing process. Using an integrated approach and dynamic working system, the firm guarantees the individual goals of different clients are appreciated and addressed in the development process which in the long run leads to a partnership-based on mutual success.

Furthermore, the ability to produce its own proprietary products and provide a full-service CRO offering is one of the core differentiators of Fido Pharma among its competitors. The dual ability enables the firm to present seamless end-to-end solutions to the clients without hindering their work process, which lowers the risks of multi-vendor projects.

Manufacturing activities undertaken by the company involve a vast collection of high-quality enzymes that find application in the pharmaceutical, food, cosmetic and specialty chemicals industries.

These enzymes include some of the popular proteolytic and metabolic enzymes that are manufactured under quality control systems where the quality is often maintained and complies with regulatory standards.

Also to note, Prabhat Singh (CEO & Managing Director), Tejal Singh (Managing Director), Rituraj Singh (Director) and Fido Pharma's management team brings unparalleled experience in the fields of pharmaceutical manufacturing, regulatory affairs and research and development which keeps Fido Pharma on track as far as innovation, customer satisfaction and constant development are concerned; devising future-ready solutions that not only meets market demand and expectations but also address the changes anticipated in the industry itself.

Integrated Products and Services

Fido Pharma also has an impressive probiotic portfolio with over 30 scientifically validated strains to address a variety of health needs such as digestive support, metabolic regulation, immune health, and overall wellness. The strains are carefully selected and, once selected, the strain is cultivated with close controls on its stability, viability, and functional utilisation; thereby ensuring the finished product conforms to the industry standard.

Although enzymes and probiotics are at the core of Fido Pharma's product offering, its expertise goes beyond, to include nutraceuticals and other dietary supplements to help keep up with changing consumer demand for integrative and preventative health as they can develop and manufacture their own products and ingredients in-house.

The products are rigorously tested for potency, bioavailability, and shelf-life stability, and carefully formulated so they can guarantee active ingredient quality in its own products and also be a partner to develop and prepare the product for the market.

Fido Pharma offers a far-reaching service portfolio which covers all aspects of product development. Its bio-pharmaceutical and biologics assay development services provide custom-designed assays that measure product activity, stability, and clinical performance accurately.

Additionally, it provides commercialization support services, including assistance with market access strategies, product registrations, and regulatory involvement. For instance, Fido Pharma's Outcomes Research Services and Real World Evidence Services can provide clients with ways to establish long-term safety, efficacy, and market value of their products.

Client-Centric Solutions Deliverability

The skillset to solve client problems is a key strength of Fido Pharma and its brand name in the industry. Typical problems clients experience include raw material substandard quality issues, fluctuating distribution channels, variable assay readings, and inconsistent record of regulations. Fido Pharma actively overcomes these challenges by having its vertically integrated model, where raw materials are carefully supplied and manufacturing steps are followed as per protocols.

This makes sure that the quality aspect faces no hindrance. Furthermore, contracting out all aspects of the research and manufacturing process to different companies, minimizes the coordination gaps and communication delays by engaging in multi-party collaborations.

The quality assurance teams within the organization collaborate directly with the clients to verify protocols of assays on specific products, resolve any technical problems, and even avail specialized regulatory records that can easily help in the successful approval of a product to be commercialized in any region across the world.

The relationship between Fido Pharma and its clients is marked with proactive problem-solving, open communication and scientific collaboration. Most customers turn to Fido Pharma when there have been hold ups, quality control problems, or a disintegrated workflow of other suppliers.

This firm has always stood out due to its approach of assigning dedicated multidisciplinary teams that are able to work together throughout the development period. The firm’s competent team includes scientists, regulatory experts, and quality specialists who are always on their toes to carry out regular project updates, technical discussions, and troubleshooting.

Also to note, Fido Pharma's client-focused approach fosters problem-solving on time and encourages ongoing adaptations to its clients while consistently delivering reliable results.

Global Compliance & Expansion

The company's focus on quality is backed by a robust certification program and adherence to international manufacturing standards. Fido Pharma's facilities are ISO 9001:2015 certified, which comply with Good Manufacturing Practices (GMP). This guarantees that its products meet both safety and efficacy standards. To show its commitment to compliance, the firm’s facilities have many international certifications, including WHO-GMP, HACCP, Halal, FSSAI, and U.S. FDA registration.

These certifications enable it to offer different products to a diverse, international client base with the confidence that its products and processes meet the most stringent regulatory expectations. In addition to its commitment to compliance, Fido Pharma's transparency around environmental health and manufacturing further reassures its clients about sustainable sourcing and ethical production practices.

Today, Fido Pharma's global customer reach continues to grow, and has a reach today to supply products and services to over twenty of its compliance countries including very regulated markets such as the USA, Germany, Canada, Japan, Korea, and China.

Its manufacturing presence Unit 1 and Unit 2 with the manufacturing location in Panchkula (Haryana) has been strategically set up to provide a well-positioned manufacturing presence for the effectively-scalable manufacture with the same quality to those clients nationwide.

Such spatially distributed infrastructure gives the company a logistic positional freedom as it ensures that the company is able to efficiently adapt to altered customer needs and market demands.

The Robust Future Roadmap

Going forward, Fido Pharma aims to expand internationally by focusing on regulatory harmony, scientific innovation, digital merger and sustainability. It is currently eyeing more collaboration with endemic clinical partners which include expanding real-world evidence capabilities and investing in other advanced formulations, including microencapsulation and sustained-release systems.

It is also embracing digital technology such as electronic data capture and AI analytics with a view to enhancing clinical efficiency. The firm is also undertaking joint research with academic research partners and biotechnology companies, which makes it a co-developer of next-generation enzyme, probiotic, and nutraceutical.